Avicanna and Ei. Ventures Enter into an Agreement to Develop and Commercialize Adaptogen Nutraceuticals
Avicanna Inc. ("Avicanna
" or the
) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a
biopharmaceutical company focused on the development,
manufacturing, and commercialization of plant-derived
cannabinoid-based products is pleased to announce that the Company
has entered into an Intellectual Property Licensing & Royalty
”) with Ei.Ventures, Inc. (“Ei.”)
to develop and commercialize functional fungi-based products.
“Over the past six years our team established a
scientific platform that has led to the commercialization of
several products across international commercial channels in the
regulated cannabis industry. As a part of our continued growth, we
are thrilled to be entering into this agreement where our goal will
be to demonstrate our scientific capabilities across alternative
natural products and developing new fungi-based functional
products. We look forward to working towards developing the new
products in the nutraceutical area in a standardized and
evidence-based way, as we have with our initial cannabinoid-based
products.” stated Aras Azadian, CEO of Avicanna.
The initial focus of the research and
development efforts will be on functional, apoptogenic, fungi-based
formulations in the form of consumer friendly and single dosed
products. The new product development efforts are to be led by
Avicanna’s R&D team, leveraging the company’s existing
scientific platform and proprietary delivery systems to develop
appropriately dosed and synergistic formulations.
“We are excited to enter into this agreement with Avicanna to
develop and commercialize the Psilly™ brand of products, starting
with functional mushroom blends, gummies and chocolates, and which
relationship can potentially evolve to botanical psychedelic
pharmaceutical products” states David Nikzad, CEO of Ei. Nikzad
continues, “we believe in the Avicanna team and their mission to
develop advanced and proprietary plant-based formulations, and we
will bring our blockchain, Web3 and Metaverse assets to scale and
support the success of the products developed under our
About Avicanna Inc.
Avicanna is a commercial-stage international
biopharmaceutical company focused on the advancement and
commercialization of evidence-based cannabinoid-based products for
the global medical and pharmaceutical market segments. Avicanna has
an established scientific platform including R&D and clinical
development that has led to the commercialization of more than
thirty products across various market segments:
Medical Cannabis & Wellness
Products: Marketed under the RHO Phyto™ brand these
medical and wellness products are a line of pharmaceutical-grade
cannabinoid products containing varying ratios of cannabidiol
(“CBD”) and tetrahydrocannabinol (“THC”). The product portfolio
contains a full formulary of products including oral, sublingual,
topical, and transdermal deliveries that have controlled dosing,
enhanced absorption and stability studies supported by pre-clinical
data. The formulary is marketed with consumer, patient and
medical-community education and training.
Pipeline: Leveraging Avicanna’s scientific platform,
vertical integration, and real-world evidence, Avicanna has created
a pipeline of patent-pending drug candidates that are
indication-specific and in various stages of clinical development
and commercialization. These cannabinoid-based drug candidates look
to address unmet medical needs in the areas of dermatology, chronic
pain, and various neurological disorders. Avicanna’s first
pharmaceutical preparation (Trunerox™) is in the drug registration
stage in South America.
Click to watch Avicanna’s Corporate Video 2022
SOURCE Avicanna Inc.
About Ei.Ventures, Inc.
Ei.Ventures Inc. is an early-stage tech company empowering
mental wellness through psychoactive compounds, nutraceuticals and
technology. Ei is leveraging blockchain, emerging technologies and
the Metaverse to deliver governmental approved therapeutic
treatment options that address the current global mental healthcare
pandemic. It is the goal of Ei to utilize the development of these
technologies, to create a safe, efficient, and secure way to
provide telehealth services in general and specifically to the
psychoactive therapeutics. Additional information on Ei can be
found on the Ei’s website at: https://www.ei.ventures.
For more information about Avicanna, visit www.avicanna.com,
contact Ivana Maric by email at email@example.com or follow us on
on LinkedIn, Twitter, Facebook or Instagram.
The Company posts updates through videos from the official
Company YouTube channel.
Cautionary Note Regarding Forward-Looking Information
This news release contains “forward-looking
information” within the meaning of applicable securities laws.
Forward-looking information contained in this news release may be
identified using words such as, “may”, “would”, “could”, “will”,
“likely”, “expect”, “anticipate”, “believe, “intend”, “plan”,
“forecast”, “project”, “estimate”, “outlook” and other similar
expressions. Although the Company believes that the expectations
and assumptions on which such forward looking information is based
are reasonable, undue reliance should not be placed on the
forward-looking information because the Company can give no
assurance that they will prove to be correct. Actual results and
developments may differ materially from those contemplated by these
statements. Forward-looking information is subject to a variety of
risks and uncertainties that could cause actual events or results
to differ materially from those projected in the forward-looking
information. Such risks and uncertainties include but are not
limited to current and future market conditions, including the
market price of the common shares of the Company, and the risk
factors set out in the Company’s annual information form dated
March 31, 2022 filed with the Canadian securities regulators and
available under the Company’s profile on SEDAR at www.sedar.com.
The statements in this news release are made as of the date of this
release. The Company disclaims any intent or obligation to update
any forward-looking information, whether as a result of new
information, future events or results or otherwise, other than as
required by applicable securities laws.
A photo accompanying this announcement is available at
Graphique Historique de l'Action
De Août 2022 à Sept 2022
Graphique Historique de l'Action
De Sept 2021 à Sept 2022